Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05144698 | RAPA-201 Therapy of Solid Tumors | recruiting | Phase 1 / Phase 2 | 37 | Rapa Therapeutics LLCINDUSTRY | 1 | May 14, 2025 | clinicaltrials |
| NCT06970132 | Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation | not yet recruiting | Phase 1 / Phase 2 | 102 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | May 14, 2025 | clinicaltrials |
| A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies |
| recruiting |
| Phase 1 / Phase 2 |
| 224 |
| CytosinLab Therapeutics Co., Ltd.INDUSTRY |
| 1 |
| May 14, 2025 |
| clinicaltrials |
| NCT05263960 | A Study of CM350 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 248 | Keymed Biosciences Co.LtdINDUSTRY | 1 | May 4, 2025 | clinicaltrials |
| NCT06955390 | Clinical Trial of HRS-4642 Plus SHR-A2102 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 32 | Henan Cancer HospitalOTHER_GOV | 1 | May 2, 2025 | clinicaltrials |
| NCT06949761 | A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation | not yet recruiting | Phase 1 / Phase 2 | 240 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Apr 29, 2025 | clinicaltrials |
| NCT06947226 | A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 188 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Apr 27, 2025 | clinicaltrials |
| NCT05736731 | A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression(EVEREST-1) | active not recruiting | Phase 1 / Phase 2 | 160 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT06669975 | A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 85 | AP Biosciences Inc.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT06895928 | A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors | recruiting | Phase 2 | 400 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 22, 2025 | clinicaltrials |
| NCT06939270 | CD73/AXL Targeted HypoSti.CAR-T Cells in CD73/AXL Positive Advanced/Metastatic Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT06928363 | A First-in-human Study of KY-0301 in Patients With Advanced Solid Tumors. | not yet recruiting | Phase 1 / Phase 2 | 212 | Novatim Immune Therapeutics (Zhejiang) Co., Ltd.INDUSTRY | 0 | Apr 15, 2025 | clinicaltrials |
| NCT04775485 | A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors(FIREFLY-1) | recruiting | Phase 2 | 141 | Day One Biopharmaceuticals, Inc.INDUSTRY | 11 | Apr 10, 2025 | clinicaltrials |
| NCT06431243 | A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 132 | Chengdu Zenitar Biomedical Technology Co., LtdINDUSTRY | 1 | Apr 10, 2025 | clinicaltrials |
| NCT06911333 | AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors(AD1208) | recruiting | Phase 1 / Phase 2 | 36 | Avelos Therapeutics Inc.INDUSTRY | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06906731 | A Study of SHR-9803 for Injection in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 27 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 2, 2025 | clinicaltrials |
| NCT05269316 | Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 61 | Impact Therapeutics, Inc.INDUSTRY | 4 | Apr 1, 2025 | clinicaltrials |
| NCT05784688 | Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 140 | TiumBio Co., Ltd.INDUSTRY | 2 | Mar 30, 2025 | clinicaltrials |
| NCT06895733 | Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1) | recruiting | Phase 1 / Phase 2 | 65 | Tianjin Medical University Second HospitalOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT05146440 | Multicohort Trial of Different Schemes of PM14 in Monotherapy and in Combination with Radiotherapy in Soft Tissue Sarcomas and Other Solid Tumor(PRIME) | recruiting | Phase 1 / Phase 2 | 195 | Grupo Espanol de Investigacion en SarcomasOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT05970016 | A Phase I/II Clinical Study in Patients with Advanced Solid Tumor. | recruiting | Phase 1 / Phase 2 | 56 | Beijing Tide Pharmaceutical Co., LtdINDUSTRY | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06775236 | Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 410 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Mar 19, 2025 | clinicaltrials |
| NCT04585035 | Study to Evaluate D-1553 in Subjects With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 180 | InventisBio Co., LtdINDUSTRY | 4 | Mar 18, 2025 | clinicaltrials |
| NCT06873854 | A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours | not yet recruiting | Phase 2 | 84 | LaNova Medicines LimitedINDUSTRY | 1 | Mar 13, 2025 | clinicaltrials |
| NCT05142423 | A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 198 | AkesoINDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT05487170 | A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1) | recruiting | Phase 1 / Phase 2 | 32 | Ranok Therapeutics (Hangzhou) Co., Ltd.INDUSTRY | 2 | Mar 4, 2025 | clinicaltrials |
| NCT06032845 | Cryoablation Combined with Tislelizumab Plus Lenvatinib in Previously Treated Solid Tumors (CASTLE-11)(CASTLE-11) | recruiting | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06173219 | Safety and Efficacy of Radiotherapy Combined with Immunotherapy for Advanced Malignant Tumors. | recruiting | Phase 1 / Phase 2 | 38 | China-Japan Friendship HospitalOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT04785196 | APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 95 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Feb 26, 2025 | clinicaltrials |
| NCT06239155 | A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 51 | Ascentawits Pharmaceuticals, LtdINDUSTRY | 1 | Feb 25, 2025 | clinicaltrials |
| NCT04165330 | Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 56 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT05862324 | TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)(TACTIC-3) | active not recruiting | Phase 1 / Phase 2 | 113 | Triumvira Immunologics, Inc.INDUSTRY | 2 | Feb 14, 2025 | clinicaltrials |
| NCT05669430 | A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies | recruiting | Phase 1 / Phase 2 | 365 | GV20 TherapeuticsINDUSTRY | 1 | Feb 13, 2025 | clinicaltrials |
| NCT06464055 | A Study of GQ1010 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 260 | GeneQuantum Healthcare (Suzhou) Co., Ltd.INDUSTRY | 1 | Feb 10, 2025 | clinicaltrials |
| NCT05662397 | A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody | active not recruiting | Phase 1 / Phase 2 | 77 | HotSpot Therapeutics, IncINDUSTRY | 3 | Feb 4, 2025 | clinicaltrials |
| NCT06549946 | Ixovex-1 Single Agent and Combination Therapy(IXACT) | recruiting | Phase 1 / Phase 2 | 18 | Psivac LtdINDUSTRY | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06038396 | A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 48 | RemeGen Co., Ltd.INDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT05205850 | A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors | recruiting | Phase 1 / Phase 2 | 135 | RemeGen Co., Ltd.INDUSTRY | 1 | Jan 27, 2025 | clinicaltrials |
| NCT06016062 | A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors | recruiting | Phase 1 / Phase 2 | 221 | RemeGen Co., Ltd.INDUSTRY | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06764628 | A Study of SHR-4375 in Subjects With Solid Tumors | recruiting | Phase 1 / Phase 2 | 208 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06787950 | Clinical Study of ASN-3186 in Patients with Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 200 | Jiangsu Yahong Meditech Co., Ltd aka AsierisINDUSTRY | 0 | Jan 22, 2025 | clinicaltrials |
| NCT06782334 | AMT-116 in Patients with Solid Tumors | recruiting | Phase 1 / Phase 2 | 144 | Multitude Therapeutics Inc.INDUSTRY | 1 | Jan 17, 2025 | clinicaltrials |
| NCT06600022 | Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours. | recruiting | Phase 1 / Phase 2 | 441 | Sinocelltech Ltd.INDUSTRY | 1 | Jan 16, 2025 | clinicaltrials |
| NCT03709680 | Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors | active not recruiting | Phase 2 | 128 | PfizerINDUSTRY | 14 | Jan 14, 2025 | clinicaltrials |
| NCT04440735 | A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 125 | Kahr MedicalINDUSTRY | 1 | Jan 9, 2025 | clinicaltrials |
| NCT05688280 | Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS(INJECTABL-1) | active not recruiting | Phase 1 / Phase 2 | 42 | Immunophotonics, Inc.INDUSTRY | 5 | Jan 8, 2025 | clinicaltrials |
| NCT06643754 | A Clinical Study of SHR-3276 for Injection in Patients With Advanced Malignant Tumors | recruiting | Phase 1 / Phase 2 | 115 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 8, 2025 | clinicaltrials |
| NCT06090266 | A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents | recruiting | Phase 1 / Phase 2 | 168 | OncoResponse, Inc.INDUSTRY | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06762327 | Ensartinib in the Treatment of ALK Positive or MET Exon 14 Skipping Anvanced Solid Tumors Excluded Lung Cancer | not yet recruiting | Phase 2 | 20 | Nanjing First Hospital, Nanjing Medical UniversityOTHER | 0 | Jan 7, 2025 | clinicaltrials |
| NCT05417321 | A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 80 | Shanghai Huaota Biopharmaceutical Co., Ltd.INDUSTRY | 2 | Jan 3, 2025 | clinicaltrials |
Data updated 23 days agoSource updated May 14, 2025source: clinicaltrials